Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Tla Targeted Immunotherapies Ab patents


Recent patent applications related to Tla Targeted Immunotherapies Ab. Tla Targeted Immunotherapies Ab is listed as an Agent/Assignee. Note: Tla Targeted Immunotherapies Ab may have other listings under different names/spellings. We're not affiliated with Tla Targeted Immunotherapies Ab, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "T" | Tla Targeted Immunotherapies Ab-related inventors


Treating conditions associated with metabolic syndrome

A method for treating a condition associated with metabolic syndrome or for treating adiposis dolorosa (ad) comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor ccr2, ccr1, ccr3, ccr4 or ccr5 immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally ccr2, ccr1, ccr3, ccr4 and ccr5 expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.. ... Tla Targeted Immunotherapies Ab

Treating mental disorders

A method for treating mental disorders such as schizophrenia, depression and bipolar disorder comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising a binding reagent capable of specifically binding to a chemokine receptor, optionally the chemokine receptor ccr9, ccr1, ccr3 and/or ccr5 immobilized directly or indirectly on the support thus removing chemokine receptor, optionally ccr9, ccr1, ccr3 and/or ccr5 expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.. ... Tla Targeted Immunotherapies Ab

Treating cancer

A method for treating cancer comprising applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor ccr7, ccr5, ccr6, ccr8, cxcr4, cxcr7, ccr4, ccr9, ccr10, cxcr3 or cxcr5 or to a treg receptor immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally ccr7, ccr5, ccr6, ccr8, cxcr4, cxcr7, ccr4, ccr9, ccr10, cxcr3 or cxcr5 or treg receptor expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.. ... Tla Targeted Immunotherapies Ab

Treating conditions associated with sepsis

A method for treating sepsis and/or respiratory distress syndrome (rds) comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor ccr5, cxcr1, cxcr2, and/or ccr2 immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally ccr5, cxcr1, cxcr2, and/or ccr2 expressing cells from the peripheral blood of the patient or subject. Various companion therapeutic methods and useful binding reagents are also described.. ... Tla Targeted Immunotherapies Ab

Treating respiratory conditions

A method for treating a respiratory conditions comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor ccr2, ccr1, ccr3, ccr5, cxcr1, cxcr2 and/or ccr7 immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally ccr2, ccr1, ccr3, ccr5, cxcr1, cxcr2 and/or ccr7 expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.. ... Tla Targeted Immunotherapies Ab

Treating multiple sclerosis

A method for treating multiple sclerosis comprises applying peripheral blood from a patient or subject to an apheresis column loaded with a solid support comprising one or more binding reagents capable of specifically binding to a chemokine receptor, optionally the chemokine receptor ccr2, ccr6, ccr3, ccr5, ccr1, cxcr3 and/or ccr9 immobilized directly or indirectly on the support thus removing one or more chemokine receptor, optionally ccr2, ccr6, ccr3, ccr5, ccr1, cxcr3 and/or ccr9 expressing cells from the peripheral blood of the patient or subject. Various companion diagnostic methods and useful binding reagents are also described.. ... Tla Targeted Immunotherapies Ab








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Tla Targeted Immunotherapies Ab in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Tla Targeted Immunotherapies Ab with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###